Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Aiforia raised almost 10 MEUR in a directed issue

Aiforia Technologies

Translation: Original comment published in Finnish on 05/23/2024 at 9:18 am EEST

The issue was fully expected, as we believe the company’s implementation of its growth strategy requires additional funding to be collected this year. The terms (EUR 3.5 per share, gross proceeds of some 10 MEUR) were quite well in line with our expectations. With the issue, the company can continue implementing its growth strategy that has progressed well without material short-term financing risks.

9.95 MEUR collected in the issue before costs

In the directed share issue announced yesterday, Aiforia will issue 2.84 million new shares. The subscription price of the shares in the issue was EUR 3.50 per share, which corresponds to a discount of some 11.4% on yesterday’s (5/22) closing price of EUR 3.95 per share. The issue was carried out in an accelerated bookbuilding process based on bids. The issue was aimed at domestic and international institutional investors and other professional investors. The new shares account for approximately 9.9% of all Aiforia shares after the issue, so the dilution is quite moderate.

The successful issue came as no surprise, as the implementation of Aiforia’s growth strategy has progressed well and we thus believe the company was in a good position in the financing negotiations. Aiforia raised gross proceeds of 9.95 MEUR in the share issue, which, after typical costs of around 5-10%, would correspond to net assets of good 9 MEUR. In our previous valuation (3/8/2024), we had included a 10 MEUR share issue in 2024 (and another one in 2025), at a price of EUR 3.10 per share, excluding costs. Considering the typical costs of approximately 5-10% for the directed issue carried out at EUR 3.5 per share, the issue was largely as expected.

Before the issue, we estimated that Aiforia will raise a total of some 20 MEUR in additional funding to enable maintaining growth investment and achieving cash-flow neutrality, so the directed issue covers around half of this. With our current forecasts, the company’s financing needs would be sufficient until the end of 2025 with the help of this issue, when the cash flow from operating activities (excl. investments) would be positive in the company’s objectives. With our forecasts, cash flow would be positive after investments in 2027, so any additional funding would presumably be raised with better visibility of the timing for achieving cash flow neutrality.

We feel the elimination of short-term financial uncertainties with expected terms is in principle positive for the company, even though a share issue carried out slightly below yesterday’s closing price may also bring short-term downward pressure to the share and room for play.

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more on company page

Key Estimate Figures08.03.2024

202324e25e
Revenue2.44.38.1
growth-%49.3 %80.1 %88.4 %
EBIT (adj.)-12.9-11.4-10.2
EBIT-% (adj.)-537.1 %-263.0 %-125.4 %
EPS (adj.)-0.50-0.44-0.39
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Imaging in this context refers to radiology, so the ambiguity you mentioned does not exist. Aiforia’s solutions are for clinical pathology and...
29 minutes ago
by Nikkoton
0
That pathology field covers a lot of ground, and I suppose it’s about interpreting all kinds of samples digitally using AI, whether we’re talking...
1 hour ago
by Salvelinus
0
Of course, it’s worth remembering here that Aiforia’s solution is for pathology and not for imaging.
1 hour ago
by Nikkoton
0
I’ve been checking the Siemens Healthineers website to see if there are any mentions. It seems like there are big medical events happening right...
1 hour ago
by Salvelinus
1
Without taking a position on the analysis itself, Nuways has a “buy” recommendation for almost every client, “under review” for a few, and a...
13 hours ago
by Verneri Pulkkinen
25
Pre-results update. Despite the share price, target €3.80 & Buy Summary: We remain upbeat on Aiforia’s Foundation Engine and its clinical and...
15 hours ago
by Opa
16
It is certainly possible that deals have also been made below the disclosure threshold. I believe there were a few such deals in H1 as well....
21 hours ago
by Jekkku
5
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.